Open Access

Carbamoylation correlates of cyanate neuropathy and cyanide poisoning: relevance to the biomarkers of cassava cyanogenesis and motor system toxicity

  • Samuel Kimani1, 4,
  • Victor Moterroso2,
  • Mike Lasarev3,
  • Sinei Kipruto1,
  • Fred Bukachi5,
  • Charles Maitai1,
  • Larry David6 and
  • Desire Tshala-Katumbay3, 7, 8Email author

DOI: 10.1186/2193-1801-2-647

Received: 15 November 2013

Accepted: 25 November 2013

Published: 2 December 2013


We sought to elucidate the protein carbamoylation patterns associated with cyanate neuropathy relative to cyanide poisoning. We hypothesized that under a diet deficient in sulfur amino acids (SAA), the carbamoylation pattern associated with cyanide poisoning is similar to that of cyanate neuropathy. Male rats (6–8 weeks old) were fed a diet with all amino acids (AAA) or 75%-deficiency in SAA and treated with 2.5 mg/kg/body weight (bw) NaCN, or 50 mg/kg/bw NaOCN, or 1 μl/g/bw saline, for up to 6 weeks. Albumin and spinal cord proteins were analyzed using liquid chromatography mass spectrometry (LC-MS/MS). Only NaOCN induced motor deficits with significant levels of carbamoylation. At Day 14, we found a diet-treatment interaction effect on albumin carbamoylation (p = 0.07). At Day 28, no effect was attributed to diet (p = 0.71). Mean number of NaCN-carbamoylated sites on albumin was 47.4% higher relative to vehicle (95% CI:16.7-86.4%). Only NaOCN carbamoylated spinal cord proteins, prominently, under SAA-restricted diet. Proteins targets included myelin basic and proteolipid proteins, neurofilament light and glial fibrillary acidic proteins, and 2', 3' cyclic-nucleotide 3'-phosphodiesterase. Under SAA deficiency, chronic but not acute cyanide toxicity may share biomarkers and pathogenetic similarities with cyanate neuropathy. Prevention of carbamoylation may protect against the neuropathic effects of cyanate.


Carbamoylation Cyanate Cyanide Neuropathy Proteomics


Dietary dependency on cyanogenic cassava and low intake in sulfur amino acid (SAA) have been implicated in outbreaks of a central motor neuron disease known as konzo. Subjects affected by the disease present with an overt spastic abnormality of their gait or a complete inability to walk (Howlett et al. 1990Tylleskar et al. 1992Tylleskar et al. 1994Chabwine et al. 2011Cliff et al. 2011Boivin et al. 2013). We recently showed that children from konzo-affected areas may also present with a pervasive cognitive dysfunction suggesting that the clinical burden associated with cassava cyanogenic intoxication has been underestimated (Boivin et al. 2013). The exact biomarkers and mechanisms of the disease remain unclear. The disease mainly affects children and women of childbearing age among sub-Saharan African populations that subsist on food products derived from insufficiently processed bitter and cyanogenic cassava.

Cassava is a carbohydrate-enriched and cyanogenic crop with a very low content in proteins and only 1-2% content in SAA, which are needed for humans to detoxify cyanide (Diasolua Ngudi et al. 2002Kassa et al. 2011 Nunn et al. 2011). It contains linamarin, a cyanogenic compound that is metabolically converted to cyanohydrins and hydrogen cyanide, a well-known mitochondrial toxin. Under normal conditions, cyanide (CN) is converted to a less toxic compound i.e. thiocyanate (SCN) via the SAA-dependent rhodanese pathway, to trace amounts of cyanate (OCN), and to 2-iminothiazoline-4-carboxylic acid. Under conditions of SAA-deficiency, oxidative detoxification pathways of cyanide are favored and there is increased production of OCN, a well-known motor system toxin (Tellez et al. 1979 Swenne et al. 1996 Spencer 1999 Tor-Agbidye et al. 1999a Zottola et al. 2009). Epidemiological studies have shown a link between cassava cyanogenic exposure, protein malnutrition, and outbreaks of konzo (Banea-Mayambu et al. 1997 Cliff et al. 2011 Nzwalo and Cliff 2011). Currently, research efforts focus on elucidating the biomarkers and mechanisms of the disease. Limited progress has been made partially due to the lack of experimental models.

We previously showed that proteomics methodologies may help unveil biomarkers of cyanogenic exposure (Kassa et al. 2011). In this study, we compared the carbamoylation patterns of cyanate neuropathy versus cyanide poisoning under a diet deficient in SAA. We hypothesized that under a diet deficient in sulfur amino acids (SAA), the carbamoylation pattern associated with cyanide poisoning is similar to that of cyanate neuropathy. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis was performed on albumin and spinal cord proteins from rodents treated with cyanide or cyanate while fed with either a normal (all amino acid-containing) diet or a diet deficient in SAA. NaOCN, or NaCN to a lesser extent, carbamoylates serum albumin. SAA deficiency exacerbates the NaOCN carbamoylation effects on select spinal cord proteins. Studies on humans affected by cassava-associated neurological diseases are needed to determine whether chronic cassava cyanogenic exposure is associated with cyanate-like carbamoylation patterns.


Motor deficits

Over the course of the study, the odds of remaining on the rotarod for at least 60s was significantly (p < 0.05) lower for the SAA-fed rats treated with NaOCN compared to those treated with NaCN or vehicle. Treatment affected the rotarod fall off time. The fall time was also significantly (p = 0.040) shorter on the last testing day in animals treated with NaOCN compared to control and NaCN groups. No statistical difference was found between NaCN relative to the control treated groups (p = 0.16) (Figure 1).
Figure 1

Rotarod performance in rats treated with normal saline (NS), NaCN or NaOCN and fed SAA-restricted diet. Treatment affected rotarod fall off time in rats. The fall time from the rotating rod decreased significantly (p <0.001) among rats treated with NaOCN compared to control and NaCN overtime.

Albumin carbamoylation

There was a significant interaction between diet and treatment with respect to mean number of assigned MS/MS spectra to carbamoylated albumin peptides (spectral counts) at 14-day time point (X^2(2df) = 5.24, p = 0.073). NaOCN overtly induced high levels of carbamoylation of albumin relative to vehicle or NaCN regardless of the diet (P < 0.001) (Table 1).
Table 1

Day 14 mean number of spectral counts (95% CI mean response) for carbamoylated albumin peptides




AAA estimates (95%CI)

SAA estimates (95%CI)


22.5 (16.5 - 30.7)

15.8 (11.2 - 22.1)


18.0 (13.0 - 25.0)

21.5 (15.7 - 29.4)


521.0 (411.0 - 660.0)

702.0 (554.0 - 888.0)


Estimated ratios (95% CI)

Estimated ratios (95% CI)


0.80 (0.51 - 1.26)

1.37 (0.86 - 2.17)]


23.2 (15.7 - 34.2)*

44.5 (29.5 - 67.3)*


28.9 (19.3 - 43.4)*

32.6 (22.0 - 48.3)*

NaOCN overtly (*) induced high levels of carbamoylation of albumin relative to vehicle or NaCN regardless of the diet.

At the 28-day time point, there was no evidence of interaction between diet and treatment with respect to mean number of spectral counts for carbamoylated albumin peptides (X^2(2df) = 3.83, p = 0.15), thereby simplifying comparisons across treatments and diets. The mean number of spectral counts for albumin carbamoylated peptides was 47.4% (95% CI: 16.7 - 86.4%) greater in NaCN-treated animals relative to their vehicle-treated counterparts (p = 0.001), regardless of diet. The carbamoylation effect was amplified in animals treated with NaOCN compared to vehicle, with the mean response for NaOCN animals being 33.9 (95% CI: 28.0 - 41.1) times as much as the mean response for vehicle (p < 0.001) or 23 (95% CI: 19.5 - 27.2) times the mean response for NaCN (p < 0.001) (Table 2). After controlling for treatment, we found no significant differences in carbamoylation that could be attributed to diet (p = 0.71).
Table 2

Day 28 mean number of spectral counts (95% CI mean response) for carbamoylated albumin peptides




AAA estimates (95% CI)

SAA estimates (95% CI)


17.3 (14.3 - 20.9)

16.9 (14.0 - 20.5)


25.5 (21.7 - 30.0)

25.0 (21.2 - 29.4)


587.0 (535.0 - 644.0)

574.0 (525.0 - 629.0)

Carbamoylation effects were significantly seen in NaCN and NaOCN-treated animals relative to their vehicle-treated counterparts, with a pronounced effect of NaOCN regardless of the diet.

When comparing the levels of albumin carbamoylation at Day 14 vs. Day 28, we found no evidence of an interaction between diet and treatment (X2(2df) = 2.27, p = 0.32). With the exception of animals treated with NaCN under the normal AAA diet, the relative change in levels of carbamoylation was not significant. In the NaCN/AAA group, the mean number of spectral counts for carbamoylated albumin peptides was estimated to increase 55% (95% CI: 20 - 101%; p = 0.001) over the 14-day span. All other entries, however, showed relative changes not significantly different (p ≥ 0.15) from unity (Table 3).
Table 3

Day 28/Day14 ratios (95% CI) of mean numbers of spectral counts for carbamoylated albumin peptides




AAA ratios (95% CI)

SAA ratios (95% CI)


1.06 (0.80 - 1.40)

0.80 (0.61 - 1.07)


1.55 (1.20 - 2.01)*

1.18 (0.91 - 1.53)


1.17 (0.94 - 1.46)

0.89 (0.71 - 1.11)

Comparison of the levels of albumin carbamoylation at day 28 vs. day 14 revealed increased carbamoylation (*) in the group of animals treated with NaCN and fed with a normal diet.

Spinal cord proteomics

On the last experimental day, we found a differential pattern of susceptibility to carbamoylation in spinal cord proteins. Carbamoylation was almost exclusively induced by NaOCN so that comparisons between diets were limited to this one neurotoxicant. NaOCN-targeted proteins included myelin basic protein (MBP), myelin proteolipid protein (MPP), neurofilament light polypeptide (NFLP), glial fibrillary acidic protein (GFAP), and 2', 3' cyclic-nucleotide 3'-phosphodiesterase. MBP was 18.8% (95% CI: 2.3 - 38.1%; p = 0.024) more carbamoylated in animals under the SAA-restricted diet relative their AAA counterparts. With regard to MPP, animals in the SAA-restricted diet had 23.3% (95% CI: 5.8 - 43.7%; p = 0.007) more carbamoylation sites compared to their AAA counterparts. Similarly for NFLP, the SAA-restricted diet had an impact on carbamoylation. Under the SAA-restricted diet, the animals had 39% (95% CI: 2.6 - 88.2%; p = 0.03) more carbamoylation sites relative to their AAA counterparts. For GFAP, the SAA-deficient group had 34.2% (95% CI: 5.9 - 69.9%; p = 0.02) more carbamoylation sites relative to the AAA-group. With regard to 2', 3' cyclic-nucleotide 3'-phosphodiesterase, the SAA-restricted diet produced an average number of carbamoylation sites that was 2.85 (95% CI: 1.8 - 4.5; p < 0.001) times the corresponding average response of animals fed the normal AAA diet (Table 4).
Table 4

NaOCN-induced mean numbers of carbamoylated sites (95% CI the mean response) on spinal cord proteins


AAA Diet

75% SAA-Deficient diet

Myelin basic protein

78.25 (70.0 - 87.4)

93 (84.0 – 102.0)

Myelin proteolipid protein

74 (66.0 – 82.9)

91.25 (82.4 – 101.0)

Neurofilament light polypeptide

48.75 (39.0 – 60.8)

67.75 (55.0 - 83.4)

Glial fibrillary acidic protein

30 (25.1 - 35.9)

40.25 (34.5 - 47.0)

2', 3' cyclic-nucleotide 3'-phosphodiesterase

6.5 (4.4 – 9.6)

18.5 (14.6 – 23.5)

Carbamoylation pattern in spinal cord proteins indicates an exacerbating effect of the SAA-deficient diet, mostly for 2', 3' cyclic-nucleotide 3'-phosphodiesterase.

None of the animals in the Vehicle- or NaCN-treated groups (either diet) had any carbamoylated sites for MBP or GFAP. For MPP, only one animal had 1 carbamoylated site in the Vehicle/AAA group; all other Vehicle and NaCN treatments (both diets) were otherwise uniformly silent. For the NFLP, only one animal had 1 carbamoylated site in the NaCN/SAA group; all other Vehicle and NaCN treatments (both diets) were otherwise uniformly silent.


We used state-of-the art proteomic methodologies to reveal differential carbamoylation patterns associated with cyanate neuropathy versus cyanide poisoning under conditions of dietary deficiencies in SAA. Results indicate that carbamoylated albumin may be a useful marker of exposure to cyanate and carbamoylating derivatives or precursors such as urea. Only NaOCN induced motor deficits and significant carbamoylation of albumin and select spinal cord proteins. On the assumption that these findings would hold true for additional experimental time points and time dependent correlations between levels of carbamoylation and NaOCN-induced deficits in a large sample of rats, our results suggest that cyanate neuropathy may be mediated through carbamoylation. This proposal is consistent with earlier studies that have shown a positive correlation between memory deficits and levels of carbamoylation in rat brain (Crist et al. 1973) or suggested that carbamoylated albumin may be clinically used to predict risks for neuropathy in uremic patients (Kraus and Kraus 2001Berg et al. 2013Kalim et al. 2013). The observed pattern of carbamoylation is consistent with the myelinotoxic effects of cyanate as previously reported (Ohnishi et al. 1975Tellez-Nagel et al. 1977Tellez et al. 1979). NaOCN targets include major myelin proteins and corresponding binding proteins such as neurofilament light polypeptide, glial fibrillary acidic protein, and 2', 3' cyclic-nucleotide 3'-phosphodiesterase; with the latter showing a greater carbamoylation effect. The impact of NaOCN on 2', 3' cyclic-nucleotide 3'-phosphodiesterase and, hence, functions of 2',3'-cyclic nucleotides to 2'-nucleotides in relation to microtubules and cytoskeleton organization, and cell survival, needs further attention. Establishing a model of cytoskeletal disorganization in response to cyanogenic poisoning may be relevant for testing of drug candidates including the neuroprotective peptide NAP (Zemlyak et al. 2009). The aforementioned pattern of protein susceptibility to carbamoylation should inform such studies to elucidate the exact pathways and mechanisms leading to cyanate neuropathy (Han et al. 2013).

The exacerbating effect of dietary SAA-deficiency on the carbamoylation of the aforementioned proteins has yet to be explained. In serum, SAA deficiency had no impact on the carbamoylation of albumin after 28-days of treatment with cyanate. This may possibly be explained by a “sulfur buffering effect” by abundant serum sulfur donors including albumin (Westley et al. 1983). Lack of increase in cyanate carbamoylation on day 28 relative to day 14 may be due to a metabolic clearance of carbamoylated proteins. For cyanide, however, the increase in levels of carbamoylation could simply portray a cumulative effect of cyanide detoxification with cyanate production and subsequent carbamoylation of albumin. This proposal would need, however, to be confirmed with quantitative measures of tissue contents in cyanide, cyanate, and SAA; which, along with a small sample size, are among the limitations of this study.

Within our study time frame, we failed to confirm the primary hypothesis that under SAA deficiency, acute cyanide toxicity induces carbamoylation patterns similar to that of cyanate neuropathy. However, in light of the observed response on albumin, chronic exposure to cyanide may conceivably lead to greater carbamoylation effects. This hypothesis should be tested on subjects chronically exposed to cyanide notably those living in konzo-affected areas. In these undernourished subjects, cyanide is hypothesized to undergo oxidative detoxification with subsequent increase in the production of cyanate, a well-known carbamoylating neurotoxin. The neurotoxic insults seen in these subjects could arise from a “multiple hit” process that combines of a direct mitochondrial hit by cyanide, a protein hit through carbamoylation, and a thiol-redox hit due to SAA-deficiency (Tor-Agbidye et al. 1999aTor-Agbidye et al. 1999bKassa et al. 2011Berg et al. 2013). Since only NaOCN-treated animals developed motor toxicity and carbamoylation of spinal cord proteins, our findings are in favor of a recent proposal that suggests that blocking carbamoylation may have neuroprotective effects in uremic subjects (Berg et al. 2013).


The carbamoylation and neurotoxicity effects of cyanate may be influenced by diet with an exacerbating effect of dietary deficiency in sulfur amino acids. Cyanate hits proteins that are important in maintaining the shape and organization of the cytoskeleton, and hence, supporting mechanisms of neuronal survival. Proteins targets included myelin basic and proteolipid proteins, neurofilament light and glial fibrillary acidic proteins, and 2', 3' cyclic-nucleotide 3'-phosphodiesterase. Under SAA deficiency, chronic but not acute cyanide toxicity may share biomarkers and pathogenetic similarities with cyanate neuropathy. Prevention of carbamoylation may protect against the neuropathic effects of cyanate. Studies on the biomarkers and mechanisms of food (cassava) associated neurological diseases should consider the potential role of cyanate and its carbamoylation effects as endpoints of interest both at the experimental, clinical, and public health standpoints.

Materials and methods


Sodium cyanide (NaCN CAS No. 143-33-9, 97.2% purity) and cyanate (NaOCN CAS No. 917-61-3, 96% purity) were bought from Sigma–Aldrich (St. Louis, MO) and stored at room temperature. All other laboratory reagents were of analytical or molecular biology grades.


Young adult male heterozygous rats (Crl: NIH-Fox1 rnu/Fox 1+, 6–8 weeks old) (N = 52), weighing 140-210 g upon arrival were donated by Professor Neuwelt, Department of Neurology, Oregon Health & Science University (OHSU). They were caged in an animal room maintained on a 12/12 h light/dark cycle in the Center for Research on Occupational and Environmental Toxicology (CROET). Food and water were given ad libitum. Experimental protocols were approved by the OHSU institutional animal care and use committee (IACUC).

Diet and dosing regimens


Custom-synthesized isonitrogenous rodent diet with either all amino acids (AAA-diet; code TD09460) or lacking 75% of the SAA-content relative to the control diet (SAA-deficient diet; code TD09463) were purchased from Harlan (Madison, WI) and stored at 4°C until use. We chose a 75%-deficient but not free SAA to allow for animal survival and cyanide detoxification since previous experimentation showed animals fed with SAA-free chow had dramatic weight loss and muscle weakness (Tor-Agbidye et al. 1999a).

Dosing regimens

Animals were first acclimated for a 5-day period on a diet consisting of 4:1 portions of normal rodent chow (PMI Nutrition International, NJ) with either AAA-diet (N = 28) or 75%-SAA deficient diet (N = 24). On the 6th day, they were assigned to experimental groups (N = 7-10/group) and treated intraperitoneally (one injection per day) for up to 6 weeks as follows: (Banea-Mayambu et al. 1997) AAA-diet, 2.5 mg/kg body weight (bw) NaCN; (Berg et al. 2013) AAA-diet, 50 mg/kg bw NaOCN; (Boivin et al. 2013) AAA-diet, equivalent amount of vehicle (1 μl/g bw saline); (Chabwine et al. 2011) SAA-deficient diet, 2.5 mg/kg bw NaCN; (Cliff et al. 2011) SAA-deficient diet, 50 mg/kg bw NaOCN; (Crist et al. 1973) SAA-deficient diet, equivalent amount of vehicle (1 μl/g bw saline). Dose selection for cyanide was informed by previous findings of sublethal and/or lethal cyanide poisoning prior to konzo outbreaks (Banea-Mayambu et al. 1997). Cyanate was given at doses similar to doses known to induce neuropathy in humans (Ohnishi et al. 1975).

Specific protocols

Animal observations

Rodents were examined daily in an open field for physical signs including walking difficulties, tremors and hind limb extension reflexes, which were elicited when the animal was gently raised by the tail. Motor function was assessed by animal performance on an accelerating rotating rod. Animals were individually placed on rotating rods in a software-driven rotarod apparatus (AccuScan Instruments, Inc., Columbus, OH) set in an accelerating mode. The rotation speed was gradually increased from 5 to 25 r.p.m. The apparatus had an automatic system for fall detection via photobeams. Rotarod performance was analyzed to estimate how odds of remaining on the rod for at least 60 seconds changed over time. Testing was carried out only in animals maintained on SAA diet to determine whether SAA dietary restriction had an impact on the toxicity of cyanide, our main experimental paradigm of interest.

Tissue preparation for proteomics

Serum samples were obtained on day 14 and 28 of the study period. Blood was collected from the salphenous vein using vacutainer tubes with no anticoagulants from all rats and kept overnight at 4°C. The serum was then collected in sterile tubes and centrifuged at 15,000 rpm for 15 min at 4°C. Serum was aliquoted in cryotubes and stored at -80°C till later LC-MS/MS studies. At study termination, rats were deeply anesthetized with 4% isofluorane (1 l oxygen/min) and transcardially perfused with saline through the ascending aorta to remove the remaining blood. The spinal cords were dissected out, flash-frozen in liquid nitrogen, and stored at -80°C. Prior to LC-MS/MS studies, the frozen spinal cord tissue was thawed by adding 500 μl of 100 mM ammonium bicarbonate, and the tissue was uniformly dispersed by 3X15 sec of sonication (Sonic Dismembranator, Model 60, Fisher Scientific). Samples were then centrifuged at 12,000 g for 30 min at 4°C, the supernatant removed, the pellet re-suspended and centrifugated, and the two supernatants pooled. The pellet was then re-suspended in 250 μl 100 mM ammonium bicarbonate by 5 sec of sonication as before. The protein content of the spinal cord soluble fraction, suspended pellet, and serum samples were then determined using the BCA assay (Pierce Chemical, Rockford, IL). The equivalent of 50 μg portions of the two spinal cord fractions and serum were then dried by vacuum centrifugation in preparation for trypsin digestion.

Protein digestion

Fifty μg portions of dried serum, soluble and insoluble spinal cord fractions were dissolved in 50 μl of 100 mM ammonium bicarbonate containing 1 mg/ml of Rapigest detergent (Waters Corp., Milford, MA). Eight μl of 50 mM dithioerythritol (DTT) solution was then added and the samples incubated for 60 min at 60º C, followed by addition of 8 μl of 150 mM iodoacetamide solution and incubation at room temperature for 30 min. An additional 16 μl of 50 mM DTT was then added, samples incubated at room temperature for an additional 15 min, and 20 μl of 0.1 μg/μl proteomics grade trypsin added (Sigma Chemical Co., St Louis, MO). Following an overnight incubation at 37°C, samples were acidified by addition of 0.5% trifluoroacetic acid (final concentration), incubation at 37°C for 45 min, centrifugation at 13,000 g for 10 min, and the supernatant frozen prior to analysis of peptides by mass spectrometry.

Mass spectrometric analysis

Ten μg samples of peptide digests were injected onto a trap cartridge (Michrom Bioresources, Auburn, CA) at 20 μl/min, samples were washed for 5 min with 2% acetonitrile, 0.1% formic acid, and the trap cartridge placed in-line with a 0.5 × 250 mm SB-C18 reverse phase column (Agilent Technologies, Santa Clara, CA). Peptides were then eluted using a 200 min gradient of 7-30% acetonitrile containing 0.1% formic acid at a flow rate of 10 μl/min. Peptide m/z values (MS spectra) and fragment ions (MS/MS spectra) were collected using an LTQ linear ion trap mass spectrometer (Thermo Scientific, San Jose, CA) with an ion max electrospray source fitted with a 34Ga metal needle. Each survey MS spectrum from 400–2000 m/z was followed by 3 data-dependant MS/MS spectra on the 3 most intense ions found in each survey MS spectrum. The instrument used the dynamic exclusion feature of its control software to ignore previously analyzed ions (repeat count of 1, maximum exclusion list of 50, and 30 sec exclusion time), a tune file configured with one μscan, a maximum ion accumulation time of 200 m/sec, and AGC targets of 30,000 and 10,000, respectively, for MS and MS/MS spectra.

MS/MS spectra from each analysis were converted to dta files using Bioworks 3.3 (Thermo Scientific) and each MS/MS spectrum matched to peptide sequences in a database using the program Sequest (Version 27, rev. 12, Thermo Scientific). Searches were performed with a static modification of +57 on cysteines for carboxyimidomethylation, and differential modifications of +16 for oxidation of methionines, and +43 for carbamoylation of lysines. The search also used trypsin specificity. A database of rat sequences was created from the Uniprot database (Swiss Bioinformatics Institute, Geneva, Switzerland) downloaded in Feb. 2011 (15,524 entries), the sequences of common contaminants added, and the database amended with sequence reversed entries to estimate peptide false discovery rates. Sequest results were then processed using the program Scaffold (version 4.0.5, Proteome Software, Portland, OR) to produce a list of identified peptides and their carbamoylation sites. Peptide and protein confidence levels of 95% and 99% were used, and a minimum of 2 unique peptides matching each protein entry was required.

Since few carbamoylated peptides were detected in the soluble fraction of spinal cord, further analysis to test for differences in the level of carbamoylation between different treatment groups was only performed for serum and spinal cord insoluble fractions. Differences in levels of carbamoylation in various treatment groups was determined by tabulating the numbers of MS/MS spectra assigned to carbamoylated peptides from albumin in serum digests, and the proteins myelin basic protein, neurofilament light polypeptide, 2’3’-cyclic-nucleotide 3’-phosphodiesterase, myelin proteolipid protein, and glial fibrillary acidic protein in digests of water-insoluble proteins from spinal cord. Inclusion lists for each of the identified carbamolyated peptides was created by specifying the m/z value for each in the instrument’s control software. This maximized the collection of MS/MS spectra for carbamoylated peptides during the quantitative analysis so that a shorter data collection period was required. This mass spectrometric analysis was identical to those described above. However they used a 60 min gradient, inclusion lists specifying the m/z values of the targeted carbamoylated peptides, and the dynamic exclusion feature of the instrument’s control software was disabled. Differences in the level of carbamoylation in various sample groups was then calculated by summing the numbers of MS/MS scans (spectral counts) assigned to carbamoylated peptides from the target proteins in each sample. The MS/MS scans collected during the analysis were again searched using Sequest using the same database and differential searches for modified peptides as before. However, due to the size of the result files, the Sequest results were filtered using PAW software (Wilmarth et al. 2009), which controlled peptide false discovery using numbers of matches to the sequence reversed entries. Peptides identified as being carbamoylated were separately filtered from unmodified peptides to maintain their false discovery rate below 5%. The linearity of the carbamoylation detection was tested by mixing protein digests from cyanate and vehicle treated animals from the sulfur deficient diet group (Figure 2). The numbers of identified carbamoylated peptides as a function of percent cyanate treated serum or spinal cord protein was determined following Sequest searches and filtering of MS/MS data using Scaffold as described above.
Figure 2

Tryptic digests from serum (A) and insoluble spinal cord proteins (B) from cyanate-treated and vehicle-only treated rats were mixed and analyzed by LC-MS/MS using an inclusion list for the carbamoylated peptides. The resulting numbers of MS/MS scans assigned to carbamoylated peptides (spectral counts) were plotted as a function of the % serum and insoluble spinal cord protein from cyanate-treated rats to determine the linearity of the carbamoylation assay for serum albumin and insoluble spinal cord proteins.

Statistical analysis

The rotorod performance was analyzed using generalized estimating equations (GEE) to estimate the odds of remaining on the accelerating rotating rod for at least 60s changed over time (per each additional day of treatment). At study termination, a secondary analysis of the performance on the rotorod was conducted. An overall (log-rank) test on the time needed to fall off the rotorod among the three groups was carried out. Numbers of carbamoylated sites per protein were assumed to follow a Poisson distribution with the mean number of sites dependent upon diet, treatment, or the interaction between the two. GEE was again used to account for the duplicate samples collected within each animal. Statistical significance was set at 0.05 (0.10 for interaction effects); all p-values are two-sided and confidence intervals set to 95% coverage.



This work as supported by supported by the National Institutes of Health, Bethesda, MD [NIEHS and FIC grants number R21ES017225 and R01ES019841]; and a fellowship from the International Society for Neurochemistry/Committee for Aid and Education in Neurochemistry to Samuel Kimani. Laboratory animals were donated by Professor Neuwelt, Department of Neurology, Oregon Health & Science University (OHSU).

Authors’ Affiliations

Department of Pharmacology and Pharmacognosy, University of Nairobi
Department of Comparative Medicine, Oregon Health & Science University (OHSU)
Center for Research on Occupational & Environmental Toxicology, OHSU
School of Nursing Sciences, University of Nairobi
Department of Medical Physiology, University of Nairobi
Biochemistry and Molecular Biology & Proteomics Shared Resource, OHSU
Department of Neurology, OHSU
Center for Research on Occupational and Environmental Toxicology & Department of Neurology, Oregon Health & Science University


  1. Banea-Mayambu JP, Tylleskar T, Gitebo N, Matadi N, Gebre-Medhin M, Rosling H: Geographical and seasonal association between linamarin and cyanide exposure from cassava and the upper motor neurone disease konzo in former Zaire. Trop Med Int Health TM IH 1997, 2: 1143-1151. 10.1046/j.1365-3156.1997.d01-215.xView ArticleGoogle Scholar
  2. Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, Ramma W, Parikh SM, Steen H, Friedman DJ, Danziger J, Wanner C, Thadhani R, Karumanchi SA: Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013, 5: 175ra129.View ArticleGoogle Scholar
  3. Boivin MJ, Okitundu D, Makila-Mabe Bumoko G, Sombo MT, Mumba D, Tylleskar T, Page CF, Tamfum Muyembe JJ, Tshala-Katumbay D: Neuropsychological effects of konzo: a neuromotor disease associated with poorly processed cassava. Pediatrics 2013, 131: e1231-1239. 10.1542/peds.2012-3011View ArticleGoogle Scholar
  4. Chabwine JN, Masheka C, Balol'ebwami Z, Maheshe B, Balegamire S, Rutega B, Wa Lola M, Mutendela K, Bonnet MJ, Shangalume O, Balegamire JM, Nemery B: Appearance of konzo in South-Kivu, a wartorn area in the Democratic Republic of Congo. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 2011, 49: 644-649.View ArticleGoogle Scholar
  5. Cliff J, Muquingue H, Nhassico D, Nzwalo H, Bradbury JH: Konzo and continuing cyanide intoxication from cassava in Mozambique. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 2011, 49: 631-635.View ArticleGoogle Scholar
  6. Crist RD, Grisolia S, Bettis CJ, Grisolia J: Carbamoylation of proteins following administration to rats of carbamoyl phosphate and cyanate and effects on memory. Eur J Biochem /FEBS 1973, 32: 109-116. 10.1111/j.1432-1033.1973.tb02585.xView ArticleGoogle Scholar
  7. Diasolua Ngudi D, Kuo YH, Lambein F: Food safety and amino acid balance in processed cassava "Cossettes". J Agric Food Chem 2002, 50: 3042-3049. 10.1021/jf011441kView ArticleGoogle Scholar
  8. Han H, Myllykoski M, Ruskamo S, Wang C, Kursula P: Myelin-specific proteins: a structurally diverse group of membrane-interacting molecules. Bio Factors 2013, 39: 233-241.Google Scholar
  9. Howlett WP, Brubaker GR, Mlingi N, Rosling H: Konzo, an epidemic upper motor neuron disease studied in Tanzania. Brain J Neurol 1990, 113(Pt 1):223-235.View ArticleGoogle Scholar
  10. Kalim S, Tamez H, Wenger J, Ankers E, Trottier CA, Deferio JJ, Berg AH, Karumanchi SA, Thadhani RI: Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. Clinical journal of the American Society of. CJASN: Nephrology; 2013.Google Scholar
  11. Kassa RM, Kasensa NL, Monterroso VH, Kayton RJ, Klimek JE, David LL, Lunganza KR, Kayembe KT, Bentivoglio M, Juliano SL, Tshala-Katumbay DD: On the biomarkers and mechanisms of konzo, a distinct upper motor neuron disease associated with food (cassava) cyanogenic exposure. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 2011, 49: 571-578.View ArticleGoogle Scholar
  12. Kraus LM, Kraus AP Jr: Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001, 78: S102-107.View ArticleGoogle Scholar
  13. Nunn PB, Lyddiard JR, Christopher Perera KP: Brain glutathione as a target for aetiological factors in neurolathyrism and konzo. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 2011, 49: 662-667.View ArticleGoogle Scholar
  14. Nzwalo H, Cliff J: Konzo: from poverty, cassava, and cyanogen intake to toxico-nutritional neurological disease. PLoS Negl Trop Dis 2011, 5: e1051. 10.1371/journal.pntd.0001051View ArticleGoogle Scholar
  15. Ohnishi A, Peterson CM, Dyck PJ: Axonal degeneration in sodium cyanate-induced neuropathy. Arch Neurol 1975, 32: 530-534. 10.1001/archneur.1975.00490500050005View ArticleGoogle Scholar
  16. Spencer PS: Food toxins, ampa receptors, and motor neuron diseases. Drug Metab Rev 1999, 31: 561-587. 10.1081/DMR-100101936View ArticleGoogle Scholar
  17. Swenne I, Eriksson UJ, Christoffersson R, Kagedal B, Lundquist P, Nilsson L, Tylleskar T, Rosling H: Cyanide detoxification in rats exposed to acetonitrile and fed a low protein diet. Fundam Appl Toxicol Off J Soc Toxicol 1996, 32: 66-71. 10.1006/faat.1996.0107View ArticleGoogle Scholar
  18. Tellez I, Johnson D, Nagel RL, Cerami A: Neurotoxicity of sodium cyanate. New pathological and ultrastructural observations in Maccaca nemestrina. Acta Neuropathol 1979, 47: 75-79. 10.1007/BF00698277View ArticleGoogle Scholar
  19. Tellez-Nagel I, Korthals JK, Vlassara HV, Cerami A: An ultrastructural study of chronic sodium cyanate-indiuced neuropathy. J Neuropathol Exp Neurol 1977, 36: 352-363.View ArticleGoogle Scholar
  20. Tor-Agbidye J, Palmer VS, Lasarev MR, Craig AM, Blythe LL, Sabri MI, Spencer PS: Bioactivation of cyanide to cyanate in sulfur amino acid deficiency: relevance to neurological disease in humans subsisting on cassava. Toxicol Sci Off J Soc Toxicol 1999, 50: 228-235. 10.1093/toxsci/50.2.228View ArticleGoogle Scholar
  21. Tor-Agbidye J, Palmer VS, Spencer PS, Craig AM, Blythe LL, Sabri MI: Sodium cyanate alters glutathione homeostasis in rodent brain: relationship to neurodegenerative diseases in protein-deficient malnourished populations in Africa. Brain Res 1999, 820: 12-19. 10.1016/S0006-8993(98)01343-2View ArticleGoogle Scholar
  22. Tylleskar T, Banea M, Bikangi N, Cooke RD, Poulter NH, Rosling H: Cassava cyanogens and konzo, an upper motoneuron disease found in Africa. Lancet 1992, 339: 208-211. 10.1016/0140-6736(92)90006-OView ArticleGoogle Scholar
  23. Tylleskar T, Legue FD, Peterson S, Kpizingui E, Stecker P: Konzo in the Central African Republic. Neurology 1994, 44: 959-961. 10.1212/WNL.44.5.959View ArticleGoogle Scholar
  24. Westley J, Adler H, Westley L, Nishida C: The sulfurtransferases. Fundam appl Toxicol Off J Soc Toxicol 1983, 3: 377-382. 10.1016/S0272-0590(83)80008-6View ArticleGoogle Scholar
  25. Wilmarth PA, Riviere MA, David LL: Techniques for accurate protein identification in shotgun proteomic studies of human, mouse, bovine, and chicken lenses. Journal of Ocular Biology, Diseases, and Informatics 2009, 2: 223-234. 10.1007/s12177-009-9042-6View ArticleGoogle Scholar
  26. Zemlyak I, Sapolsky R, Gozes I: NAP protects against cyanide-related microtubule destruction. J Neural Transm 2009, 116: 1411-1416. 10.1007/s00702-009-0252-7View ArticleGoogle Scholar
  27. Zottola MA, Beigel K, Soni SD, Lawrence R: Disulfides as cyanide antidotes: evidence for a new in vivo oxidative pathway for cyanide detoxification. Chem Res Toxicol 2009, 22: 1948-1953. 10.1021/tx900258mView ArticleGoogle Scholar


© Kimani et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.